Ingredient Spotlight12 Oct 20264 min read

Skin brightening ingredients compared: mechanism, evidence, stability and claim risk

Brightening actives are not interchangeable. Each has a different mechanism, evidence level, regulatory position and stability profile, and the claim you can make depends on all four. A working assessment of the four actives Indian brands ask about most.

By CSL Ingredient and application science team, Cosmetic Science Lab · Reviewed by Dr. Premalatha, Ph.D., Life Science, Regulatory Consultant

Evidence: clinical trials, meta-analysis, SCCS opinionMarket: India (CDSCO)For: formulators and brand owners

Melanosome transfer and pigmentation in skin, the target of brightening actives

Quick answer

Mintel's 2026 India facial skincare research tells brands to "double down on brightening" [1], so formulators are asked to deliver it with the right active, dose and proof. Niacinamide has the most controlled human data of the four; vitamin C depends on the derivative; arbutin depends on form and level; topical tranexamic acid is still emerging and sits closest to drug claims.

Take-home message for manufacturers

Assess every active on the same eight points before choosing it
Test stability under heat, humidity and long distribution routes
Never treat hydroquinone to niacinamide as a simple swap

Take-home message for brand owners

Choose the claim your evidence can carry: "brightening" and "glow" are not "whitening"
Ask for endpoint data on your finished formula
Check each active's classification before you print the pack

01How to assess a brightening active

We evaluate each active on eight points: claim, biological target, evidence level, stability in Indian climate conditions, skin-tone inclusivity, measurement endpoint, regulatory status and claim risk. Regulatory status refers to the Drugs and Cosmetics Act [2] and the Cosmetics Rules 2020 [3]. The table is a working assessment for formulation and regulatory review, not a final regulatory opinion.

Four checks between an active and a claim on pack: classify (cosmetic or drug, active, level and wording), evidence (published data plus your own study), stability (tropical conditions: heat, humidity, transport, use) and substantiate (match the endpoint to the exact claim wording). Only an active that passes all four gets a claim on pack. — **Figure 1.** Four checks stand between an active and a claim on pack.

**Table 1.** Brightening actives compared: evidence, status, stability and claim risk
Active	Biological target	Evidence level	Regulatory status (India)	Stability profile	Claim pathway	Claim risk
Niacinamide	Melanosome transfer; barrier support	Moderate	Cosmetic ingredient; confirm listing	Stable across a wide pH range	Tone-evening, glow	Lower
Vitamin C derivatives	Tyrosinase pathway; antioxidant	Varies by derivative	Cosmetic ingredient; confirm listing	Heat, light and metal sensitive	Brightening, radiance	Medium
Arbutin	Tyrosinase inhibition	Moderate	Check form and level; hydroquinone release	pH and hydrolysis dependent	Visible dark spots	Higher
Tranexamic acid	Plasmin; melanocyte signalling	Emerging (topical)	Oral is a drug; topical depends on claim	Water-soluble; test in the system	Tone-evening; avoid melasma wording	Higher

02Niacinamide: mechanism, evidence and formulation

Active profile

Niacinamide

Human evidenceSeveral controlled studies

Tropical stabilityStable over a wide pH range

Claim riskLower with tone wording

In laboratory work, niacinamide did not change melanin production in cultured melanocytes but inhibited melanosome transfer by 35–68% in a co-culture model [4]. In the clinical studies in the same paper, 5% niacinamide (18 subjects with hyperpigmentation) and 2% niacinamide with sunscreen (120 subjects with facial tanning) gave less hyperpigmentation than vehicle after 4 weeks [4]. The panels were Japanese women, so evidence across Indian skin tones should come from your own study.

For formulation, keep the pH where niacinamide is stable, since hydrolysis to nicotinic acid can cause flushing, and test tolerance at your target level. A higher percentage is not automatically a stronger claim.

Not a hydroquinone swap

In a split-face trial of 27 melasma patients over 8 weeks, 4% niacinamide gave good-to-excellent improvement in 44% of patients against 55% for 4% hydroquinone, with side effects in 18% against 29% [5]. Different efficacy, tolerability and regulatory position make it a reformulation, not a replacement.

03Vitamin C derivatives: stability across Indian climate and distribution

Active profile

Vitamin C and derivatives

Human evidenceDepends on the derivative

Tropical stabilityHeat, light, metals, oxygen

Claim riskMedium

L-ascorbic acid is potent but unstable and difficult to deliver into the skin at the optimum dose, which is why research has moved towards stable compounds [6]. Derivatives such as ascorbyl phosphates and glucosides trade some potency for stability, but each converts and performs differently in skin, so evidence cannot be borrowed from one derivative to another. Heat, light, trace metals and oxygen drive colour change and loss of activity.

Illustrative example: a vitamin C serum that stays clear on a room-temperature lab shelf turns yellow in a hot warehouse and discolours further in a delivery van exposed to heat and light; the stability protocol should include room temperature, elevated temperature, light exposure and combined conditions. — **Figure 2.** A serum that stays clear on the lab shelf can discolour after a hot summer in a warehouse or delivery van. Illustrative example.

Validate with accelerated and real-time stability studies at conditions that reflect Indian storage and transport, and protect the formula with suitable packaging.

04Arbutin, tranexamic acid and emerging actives

Active profile

Arbutin

Human evidenceModerate

Tropical stabilitypH and hydrolysis dependent

Claim riskForm and level matter

A tyrosinase inhibitor. Alpha and beta forms differ, and both can release hydroquinone, which is why the EU's SCCS set conditions for each: alpha-arbutin up to 2% in face cream and 0.5% in body lotion, beta-arbutin up to 7% in face cream, with residual hydroquinone kept as low as possible [7]. That is an EU benchmark, not an Indian limit, but it shows why form and level need a check.

Active profile

Tranexamic acid

Human evidenceStrongest in melasma, mixed routes

Tropical stabilityWater-soluble; test in system

Claim riskClose to drug claims

A 2017 meta-analysis of 11 studies and 667 participants found lower melasma severity scores across oral, topical and injected routes [8]. That is evidence in a medical condition. Using it to support a cosmetic tone claim, or naming melasma on pack, moves towards a drug claim.

Others: azelaic acid, kojic acid, 4-butylresorcinol, licorice extract and glutathione each have their own evidence, and some are restricted in other markets, so check them individually.

05Formulating across Indian skin tones and use conditions

Climate: design for heat, humidity, sweat and sebum, and validate preservation and stability under tropical conditions
Tolerance: irritation can leave marks, so well-tolerated systems matter for pigmentation claims
Panels: recruit across the tone range of your consumers and record tone by colorimetry, not self-report alone
Endpoints: match the measure to the wording, such as melanin index and expert grading for tone-evening, or reflectance and hydration for glow
Sun protection: UV exposure can undo results, so pair brightening with daily photoprotection

06How CSL takes a brightening active to a claim

Before a claim is written, each active passes the four checks in Figure 1: regulatory classification, evidence level, stability validation under tropical conditions, and claim substantiation with a matching endpoint. This is how we run formulation, testing and regulatory projects for brightening products.

For the market context behind the shift from "fairness" to "glow", read what India's claim shift means for formulation.

07Questions readers ask

Can I replace hydroquinone with niacinamide and keep the same claim?

No. They have different mechanisms, regulatory positions and evidence, so the claim must be reassessed.

Which brightening ingredient has the strongest evidence?

It depends on the claim and the form. Niacinamide has several controlled studies, while the evidence for topical tranexamic acid as a cosmetic is still emerging.

Is alpha arbutin safe in cosmetics?

The EU SCCS considers alpha-arbutin safe up to 2% in face cream and 0.5% in body lotion, provided residual hydroquinone is kept as low as possible. Check the limits that apply in your own market.

Need a brightening active assessed for your brief?

Bring a brief or a benchmark. We check classification, evidence and tropical stability, then design the claim study.

Brightening product development Talk to the CSL team

08References

Mintel. India Facial Skincare Market Report 2026. Mintel
The Drugs and Cosmetics Act, 1940, section 3(aaa) and 3(b). Indian Kanoon
Ministry of Health and Family Welfare, Government of India. The Cosmetics Rules, 2020, G.S.R. 763(E), 15 December 2020. CDSCO
Hakozaki T, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. British Journal of Dermatology, 2002; 147(1): 20–31. doi:10.1046/j.1365-2133.2002.04834.x
Navarrete-Solís J, et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. Dermatology Research and Practice, 2011; 2011: 379173. PMC3142702
Telang PS. Vitamin C in dermatology. Indian Dermatology Online Journal, 2013; 4(2): 143–146. PMC3673383
Scientific Committee on Consumer Safety (SCCS). Opinion on the safety of alpha-arbutin and beta-arbutin in cosmetic products, SCCS/1642/22, final version 31 January 2023. European Commission
Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Dermato-Venereologica, 2017; 97(7): 776–781. PubMed

CSL

CSL Ingredient and application science teamCosmetic Science Lab · Reviewed by Dr. Premalatha, Ph.D., Life Science, Regulatory Consultant · Last reviewed 12 Oct 2026Ingredient and application science

Update log